Isis Pharmaceuticals, Inc. has initiated a Phase I/II trial for ISIS-DMPKrx in patients affected by myotonic dystrophy type 1 (DM1).
In 2013, MDF launched a significant effort to increase the number of support groups for families living with DM, and we now have 14 groups across the US and Canada. Join us in celebrating the people who have brought these groups to life!
Dr. Tetsuo Ashizawa, MD, has focused his career on the search for DM treatments and care for those affected. His multi-disciplinary, patient-centric approach to care moves DM research out of the lab and into his clinic at the University of Florida.
Thanks to our community volunteers, 2014 was a great year for MDF! In addition to launching the Medical School Roadshow and Dash & Dine for DM programs, nearly $80,000 was raised by grassroots fundraising. We also grew our support group program to cover 13 US states and 1 Canadian province, with 4 new support groups currently in development!
Each year just before the holidays, we reach out to our community to ask for your support. Your contributions help us continue our efforts to find care and a cure for DM. Read our annual appeal to see what's on the horizon for 2015!